Transgene SA

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

09 4 2024 11:45:00 提供 Nasdaq GlobeNewswire

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

27 3 2024 12:45:00 提供 Nasdaq GlobeNewswire

Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer

27 3 2024 12:45:00 提供 Nasdaq GlobeNewswire

Transgene Announces Upcoming Investor Meetings

18 3 2024 12:45:00 提供 Nasdaq GlobeNewswire

Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024

06 3 2024 01:30:00 提供 Nasdaq GlobeNewswire

Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

05 3 2024 01:30:00 提供 Nasdaq GlobeNewswire

Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer

22 1 2024 11:45:00 提供 Nasdaq GlobeNewswire

Transgene Announces Financial Calendar for 2024

22 1 2024 02:00:00 提供 Nasdaq GlobeNewswire

Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050

08 1 2024 11:45:00 提供 Nasdaq GlobeNewswire

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023

04 1 2024 11:45:00 提供 Nasdaq GlobeNewswire